{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:26:27Z","timestamp":1790115987666,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Agenzia Italiana del Farmaco","award":["FARM62MC97"],"award-info":[{"award-number":["FARM62MC97"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1093\/annonc\/mdy414","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T15:17:00Z","timestamp":1536765420000},"page":"2328-2333","source":"Crossref","is-referenced-by-count":143,"title":["Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-5344","authenticated-orcid":false,"given":"P.","family":"Conte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Frassoldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Donadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gebbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maltoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rimanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cagossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pronzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giovanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Beano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Amaducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Bajardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy414_bb0010","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"18","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1093\/annonc\/mdy414_bb0015","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1093\/annonc\/mdy414_bb0020","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1093\/annonc\/mdy414_bb0025","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdy414_bb0030","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy414_bb0035","doi-asserted-by":"crossref","unstructured":"DJ Spiegelhalter, KR Abrams, JP. Myles Bayesian Approaches to Clinical Trials and Health-Care Evaluation. The Atrium, Southern Gate, Chichester, England: John Wiley & Sons, Ltd; 2004.","DOI":"10.1002\/0470092602"},{"key":"10.1093\/annonc\/mdy414_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdy414_bb0045","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"10.1093\/annonc\/mdy414_bb0050","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1200\/JCO.2015.65.1505","article-title":"Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study","volume":"34","author":"Thavendiranathan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy414_bb0055","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","article-title":"Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy414_bb0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy414_bb0065","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1470-2045(13)70384-X","article-title":"Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study","volume":"14","author":"Jones","year":"2013","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy414_bb0070","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2017.35.15_suppl.511","article-title":"Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)","volume":"35","author":"Tolaney","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy414_bb0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy414_bb0080","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/annonc\/mdu177","article-title":"Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial","volume":"5","author":"Kramar","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy414_bb0085","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy414_bb0090","article-title":"PERSEPHONE: 6 versus 12 months of adjuvant trastuzumab in patients with HER2 positive early breast cancer: randomized phase 3 non-inferiority trial with definitive 4-yr disease-free survival results","volume":"36","author":"Earl","year":"2018","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1093\/annonc\/mdy414_bb0095","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy414_bb0100","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy414_bb0105","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/12\/2328\/27342124\/mdy414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:37:33Z","timestamp":1624682253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419342310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0923753419342310"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy414","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}